PMID- 34900771
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240404
IS  - 2251-6581 (Print)
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 20
IP  - 2
DP  - 2021 Dec
TI  - Association of ACE I/D and PAI-1 4G/5G polymorphisms with susceptibility to type 
      2 diabetes mellitus.
PG  - 1191-1197
LID - 10.1007/s40200-021-00839-7 [doi]
AB  - BACKGROUND: A number of studies were carried out to assess the association of 
      angiotensin I converting enzyme (ACE) I/D and plasminogen activator inhibitor-1 
      (PAI-1-1) 4G/5G polymorphisms with susceptibility to type 2 diabetes mellitus 
      (T2DM). However, there are a few studies in Iranian patients with T2DM. Here, we 
      tested for an association of ACE I/D and PAI-1 4G/5G polymorphisms with T2DM 
      risk. METHODS: One hundred-eighteen patients with T2DM and 125 healthy subjects 
      were participates in this study. The ACE I/D (rs4340) and PAI-1 4G/5G (rs1799889) 
      polymorphisms was genotyped by conventional and PCR-RFLP assays, receptively. The 
      associations was evaluated by calculating the odds ratio (OR) and 95% confidence 
      interval (95% CI). RESULTS: The genotype distribution of ACE I/D and PAI-1 4G/5G 
      polymorphisms were not deviated from the Hardy-Weinberg equilibrium in healthy 
      controls. The ACE II, ID, and DD genotype frequencies were 18.6%, 48.3%, and 
      33.1% in the T2DM patients versus 24.0%, 45.6% and 30.4% in healthy subjects, 
      respectively. The PAI-1 4G/4G, 4G/5G, and 5G/5G genotype frequencies were 16.9%, 
      51.7%, and 31.4% in cases versus 24.8%, 57.6% and 17.6% in controls, 
      respectively. There is a significant distribution in genotype/allele of PAI-1 
      4G/4G between cases with T2DM and healthy control, but not for ACE I/D. Moreover, 
      the 5G/5G genotype is significantly (OR = 2.139, CI 95% 1.171-3.907, p = 0.013) 
      increased the risk of T2DM by two folds in the cases than healthy controls. 
      CONCLUSIONS: Our findings suggest that PAI-1 4G/5G may be likelihood risk factor 
      for the development of T2DM in the Iranian patients. The higher frequency of 
      PAI-1 5G/5G genotype in patients with T2DM revealed that individuals with the 5G 
      allele may be at higher risk of T2DM development than those with 4G. However, 
      there was no significant association between ACE I/D polymorphism and T2DM in our 
      population. Future rigorous, well-designed studies with larger sample should 
      replicate this study to confirm our findings in Iranian T2DM patients.
CI  - (c) Springer Nature Switzerland AG 2021.
FAU - Miri, Somaye
AU  - Miri S
AD  - Department of Biology, Ashkezar Branch, Islamic Azad University, Ashkezar, Iran. 
      GRID: grid.411463.5. ISNI: 0000 0001 0706 2472
FAU - Sheikhha, Mohammad Hasan
AU  - Sheikhha MH
AD  - Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, 
      Yazd, Iran. GRID: grid.412505.7. ISNI: 0000 0004 0612 5912
FAU - Dastgheib, Seyed Alireza
AU  - Dastgheib SA
AD  - Department of Medical Genetics, School of Medicine, Shiraz University of Medical 
      Sciences, Shiraz, Iran. GRID: grid.412571.4. ISNI: 0000 0000 8819 4698
FAU - Shaker, Seyed Amir
AU  - Shaker SA
AD  - Department of Anatomy School of Medicine, Iran University of Medical Sciences, 
      Tehran, Iran. GRID: grid.411746.1. ISNI: 0000 0004 4911 7066
FAU - Neamatzadeh, Hossein
AU  - Neamatzadeh H
AD  - Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, 
      Yazd, Iran. GRID: grid.412505.7. ISNI: 0000 0004 0612 5912
AD  - Mother and Newborn Health Research Center, Shahid Sadoughi University of Medical 
      Sciences, Yazd, Iran. GRID: grid.412505.7. ISNI: 0000 0004 0612 5912
LA  - eng
PT  - Journal Article
DEP - 20210703
PL  - Switzerland
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC8630325
OTO - NOTNLM
OT  - Angiotensin I Converting Enzyme
OT  - Plasminogen Activator Inhibitor-1
OT  - Polymorphism
OT  - Type 2 Diabetes
COIS- Conflicts of interestThe authors declare that they have no conflict of interest.
EDAT- 2021/12/14 06:00
MHDA- 2021/12/14 06:01
PMCR- 2022/07/03
CRDT- 2021/12/13 18:07
PHST- 2021/03/13 00:00 [received]
PHST- 2021/06/18 00:00 [accepted]
PHST- 2021/12/13 18:07 [entrez]
PHST- 2021/12/14 06:00 [pubmed]
PHST- 2021/12/14 06:01 [medline]
PHST- 2022/07/03 00:00 [pmc-release]
AID - 839 [pii]
AID - 10.1007/s40200-021-00839-7 [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2021 Jul 3;20(2):1191-1197. doi: 
      10.1007/s40200-021-00839-7. eCollection 2021 Dec.